These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23341957)

  • 1. Monoclonal antibodies against Hepatitis C genotype 3a virus like particle inhibit virus entry in cell culture system.
    Das S; Shetty RK; Kumar A; Shridharan RN; Tatineni R; Chi G; Mukherjee A; Das S; Subbarao SM; Karande AA
    PLoS One; 2013; 8(1):e53619. PubMed ID: 23341957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
    Bose M; Mullick R; Das S; Das S; Karande AA
    Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
    Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
    Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.
    Triyatni M; Vergalla J; Davis AR; Hadlock KG; Foung SK; Liang TJ
    Virology; 2002 Jun; 298(1):124-32. PubMed ID: 12093180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.
    Das S; Mullick R; Kumar A; Tandon H; Bose M; Gouthamchandra K; Chandra M; Ravishankar B; Khaja MN; Srinivasan N; Das S; Melkote Subbarao S; Karande AA
    J Gen Virol; 2017 May; 98(5):962-976. PubMed ID: 28221101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.
    Mesalam AA; Desombere I; Farhoudi A; Van Houtte F; Verhoye L; Ball J; Dubuisson J; Foung SKH; Patel AH; Persson MAA; Leroux-Roels G; Meuleman P
    Virology; 2018 Jan; 514():30-41. PubMed ID: 29128754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of human monoclonal antibodies to the envelope e2 protein of hepatitis C virus and their characterization.
    Shimizu YK; Hijikata M; Oshima M; Shimizu K; Alter HJ; Purcell RH; Yoshikura H; Hotta H
    PLoS One; 2013; 8(2):e55874. PubMed ID: 23409074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.
    Steinmann D; Barth H; Gissler B; Schürmann P; Adah MI; Gerlach JT; Pape GR; Depla E; Jacobs D; Maertens G; Patel AH; Inchauspé G; Liang TJ; Blum HE; Baumert TF
    J Virol; 2004 Sep; 78(17):9030-40. PubMed ID: 15308699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.
    Doerrbecker J; Friesland M; Riebesehl N; Ginkel C; Behrendt P; Brown RJ; Ciesek S; Wedemeyer H; Sarrazin C; Kaderali L; Pietschmann T; Steinmann E
    Hepatology; 2014 Aug; 60(2):508-20. PubMed ID: 24771613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.
    Mathiesen CK; Prentoe J; Meredith LW; Jensen TB; Krarup H; McKeating JA; Gottwein JM; Bukh J
    J Virol; 2015 Aug; 89(15):7758-75. PubMed ID: 25995244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies.
    Ashfaq UA; Qasim M; Yousaf MZ; Awan MT; Jahan S
    J Transl Med; 2011 Nov; 9():194. PubMed ID: 22074322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
    Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
    J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
    Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
    Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy.
    Kumar A; Das S; Mullick R; Lahiri P; Tatineni R; Goswami D; Bhat P; Torresi J; Gowans EJ; Karande AA; Das S
    Vaccine; 2016 Feb; 34(8):1115-25. PubMed ID: 26700891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No requirement of HCV 5'NCR for HCV-like particles assembly in insect cells.
    Zhao W; Liao GY; Jiang YJ; Jiang SD
    World J Gastroenterol; 2003 Oct; 9(10):2226-31. PubMed ID: 14562383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles.
    Cerino A; Meola A; Segagni L; Furione M; Marciano S; Triyatni M; Liang TJ; Nicosia A; Mondelli MU
    J Immunol; 2001 Oct; 167(7):3878-86. PubMed ID: 11564805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes.
    Das S; Behera P; Shewale DJ; Bodele J; Das S; Karande AA
    Arch Virol; 2024 Apr; 169(5):112. PubMed ID: 38683226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.
    Sabo MC; Luca VC; Prentoe J; Hopcraft SE; Blight KJ; Yi M; Lemon SM; Ball JK; Bukh J; Evans MJ; Fremont DH; Diamond MS
    J Virol; 2011 Jul; 85(14):7005-19. PubMed ID: 21543495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.